z-logo
open-access-imgOpen Access
Possible role of COVID-19 in the relapse of Klein-Levin Syndrome
Author(s) -
Adeel Nasrullah,
Anam Javed,
Obaid Ashraf,
Khalid Malik
Publication year - 2021
Publication title -
respiratory medicine case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.42
H-Index - 14
ISSN - 2213-0071
DOI - 10.1016/j.rmcr.2021.101445
Subject(s) - lorazepam , medicine , culprit , covid-19 , autoimmune encephalitis , neuroimaging , pediatrics , psychiatry , encephalitis , disease , infectious disease (medical specialty) , immunology , pathology , outbreak , virus , myocardial infarction
Klein-Levin Syndrome (KLS) is an extremely rare neurological disorder which can manifest as recurring spells of sleepiness, cognitive disturbances and behavioral changes. We present a novel case of KLS relapse in the setting of Coronavirus disease-19 (COVID-19). A 36-year-old male who had a known history of KLS since adolescence was admitted with sleepiness and behavioral disturbances. Brain imaging and autoimmune encephalitis work was unremarkable. The patient was diagnosed with a relapse of KLS secondary to COVID-19 based on symptomology and lack of any other precipitating factor. The patient required 8 days of hospitalization and was treated with benzodiazepines due to a history of robust response to lorazepam during a prior episode. The patient progressively improved and was discharged home on lorazepam taper. We report that similar to other neurotropic viruses, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be the culprit in instigating KLS relapse.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom